SPARC is a possible predictive marker for albumin-bound paclitaxel in non-small-cell lung cancer

Komiya, Kazutoshi; Nakamura, Tomomi; Nakashima, Chiho; Takahashi, Koichiro; Umeguchi, Hitomi; Watanabe, Naomi; Sato, Akemi; Takeda, Yuji; Kimura, Shinya; Sueoka‐Aragane, Naoko

doi:10.2147/ott.s114492

Cited by 49 publications

(37 citation statements)

References 23 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Whether SPARC expression was a predictive biomarker to Nab-PTX therapy remains controversial. Some literatures [ 36 , 37 ] found that high stromal SPARC expression in the primary tumor might be a biomarker for Nab-PTX treatment of inferior PFS and OS in advanced pancreatic ductal adenocarcinoma and better survival in NSCLC. However, another study reported that SPARC expression did not seem to be associated with the efficacy of Nab-PTX in metastatic breast cancer [ 38 ].…”

Section: Discussionmentioning

confidence: 99%

The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China

et al. 2017

View full text Add to dashboard Cite

For patients with pretreated advanced non-small cell lung cancer (NSCLC), more effective treatments are unmet. We conducted a study to explore the optimal treatment schedule of nanoparticle albumin bound paclitaxel (Nab-PTX) as a second line or later treatment for advanced NSCLC patients in China. Ninety-eight patients, who had experienced failure of prior treatment and received Nab-PTX monotherapy (130 mg/m2) on days 1, 8 of a 21-day cycle were included. The median progression-free survival (PFS) and overall survival (OS) were 4.34 months (95% confidence interval [CI] 3.508 to 5.165 months) and 11.73 months (95% CI 9.211 to 14.247 months), respectively. The objective responses rate (ORR) and disease control rate (DCR) were 22.4% and 74.5%. Prior treatment with taxane and line of therapy did not influence the efficacy of Nab-PTX. The main grade 3 to 4 toxicities were neutropenia (25.5%) and leukopenia (12.4%). Furthermore, 24 cases offered samples to assess secreted protein acidic and rich in cysteine (SPARC) expression. No statistical difference was observed in treatment efficacy between SPARC expression-negative and positive. The findings suggest that weekly Nab-PTX monotherapy is effective and well tolerated for patients with pretreated advanced NSCLC, regardless of prior taxane exposure or line of therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Nab-paclitaxel is a new paclitaxel and its tolerability, bioavailability and efficacy have been improved compared to standard paclitaxel (10). Nanoparticles of albuminpaclitaxel are absorbed by tumor cells from which paclitaxel is subsequently released to kill tumor cells (11). Compared with standard paclitaxel, nab-paclitaxel has an average particle size of 130 nm with minimal risk of capillary blockage (12) and enhances delivery of the cytotoxic agent to cancer cells.…”

Section: Figure 2 Overall Survival (Os) Of 34 Patients Who Received mentioning

confidence: 99%

Efficacy and Safety of Nab-Paclitaxel as Second-line Chemotherapy for Locally Advanced and Metastatic Non-small Cell Lung Cancer

Gong

Sun

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In this case, the patient had a remarkable response with only 28 days of administration. Of note, in a recent study, the overexpression of secreted protein acidic and rich in cysteine (SPARC), which binds to albumin, was used as marker of treatment efficiency with afatinib 22. The patient did not have any adverse effects from the afatinib 40 mg administration.…”

Section: Discussionmentioning

confidence: 96%

Second-line afatinib administration in an elderly patient with squamous cell carcinoma

Hohenforst-Schmidt

Steinheimer

Benhassen³

et al. 2017

TCRM

View full text Add to dashboard Cite

IntroductionThe majority of cases of lung cancer are still diagnosed at a late stage. At this stage, palliative therapeutic options including nonspecific cytotoxic drugs, targeted therapy, or immunotherapy can be utilized. In 2016, immunotherapy was approved in Europe for squamous cell carcinoma and adenocarcinoma. Moreover, afatinib was also approved as second-line therapy for squamous cell carcinoma.Case reportThis article presents a case of a 76-year-old male with squamous cell carcinoma who received nab-paclitaxel as first-line therapy, and his treatment was switched to the tyrosine kinase inhibitor afatinib (40 mg) after disease progression with left lung atelectasis. After receiving afatinib for only 28 days, the atelectasis resolved. No adverse effects were observed from the afatinib therapy.DiscussionIn this case, afatinib 40 mg proved to be an effective alternative treatment for an elderly patient. Treatment choice should be based on the performance status of the patient, cost-effectiveness, and drug treatment guidelines.

show abstract

SPARC is a possible predictive marker for albumin-bound paclitaxel in non-small-cell lung cancer

Cited by 49 publications

References 23 publications

The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China

The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China

Efficacy and Safety of Nab-Paclitaxel as Second-line Chemotherapy for Locally Advanced and Metastatic Non-small Cell Lung Cancer

Second-line afatinib administration in an elderly patient with squamous cell carcinoma

Contact Info

Product

Resources

About